AI-Powered Pharma Patent Litigation: The Complete Strategic Playbook for IP Teams and Portfolio Managers
A deep-dive reference for pharma IP counsel, portfolio managers, R&D leads, and institutional investors who need to turn litigation data […]
Compounding Pharmacy Patent Strategy: The Complete IP Playbook for 503A, 503B, and the Shortage Market
Key Takeaways (Executive Summary) Part 1: The Compounding Regulatory Architecture The Market Context The U.S. compounding pharmacy sector is not
Patent Data Is the Missing Ingredient Powering AI Drug Discovery
Key Takeaways (Executive Summary) Part I: The R&D Productivity Crisis and the AI Imperative The Economics Are Broken The math
Patent Data Is the Missing Ingredient Powering AI Drug Discovery Read Post »
Pharma Patent Technology Roadmaps: The Complete Intelligence Playbook for IP Teams and Portfolio Managers
How to convert raw patent filings into predictive R&D roadmaps that de-risk pipelines, price M&A targets, and identify white space
Drug Patent Data Is Your Supply Chain’s Most Accurate Forecasting Tool
The complete operational guide for pharma IP teams, portfolio managers, and supply chain leads on converting patent intelligence into production
Drug Patent Data Is Your Supply Chain’s Most Accurate Forecasting Tool Read Post »
NDC Composition Data: The Excipient R&D Roadmap That Cuts Guesswork
Part I: The $15 Billion Paradox — A Market That Grows With the Brake On The pharmaceutical excipients market is
NDC Composition Data: The Excipient R&D Roadmap That Cuts Guesswork Read Post »
Drug Patent Term: The Complete Analyst’s Playbook for Calculating, Extending, and Defending Pharmaceutical Market Exclusivity
Every day a blockbuster drug holds patent protection is worth, on average, $8.2 million in revenue. That figure makes the
Pharmaceutical Lifecycle Management and Filing Strategies: A Deep-Dive Analysis of Blockbuster Patent Fortresses
Executive Summary Between 2023 and 2028, an estimated $356 billion in worldwide branded pharmaceutical sales sit exposed to patent expiration.
Biosimilar Reverse Engineering: The Complete Technical, Regulatory, and IP Playbook
Executive Intelligence Brief Biosimilar development is not generic drug development with more paperwork. It is a $100M-to-$300M scientific undertaking that
Biosimilar Reverse Engineering: The Complete Technical, Regulatory, and IP Playbook Read Post »
